Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?

Chae, Young Kwang; Arya, Ayush; Chiec, Lauren; Shah, Hiral; Rosenberg, Ari; Patel, Sandip; Raparia, Kirtee; Choi, Jaehyuk; Wainwright, Derek A.; Villaflor, Victoria; Cristofanilli, Massimo; Giles, Francis

Published in

Impact Journals, Oncotarget, 59(8), p. 100863-100898, 2017

DOI: 10.18632/oncotarget.19809

Tools

Export citation

Search in Google Scholar

Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?

Journal article published in 2017 by Young Kwang Chae, Ayush Arya, Lauren Chiec, Hiral Shah, Ari Rosenberg, Sandip Patel, Kirtee Raparia, Jaehyuk Choi

, Derek A. Wainwright

, Victoria Villaflor, Massimo Cristofanilli, Francis Giles

This paper is made freely available by the publisher.

Full text: Download

Preprint: archiving forbidden

Postprint: archiving forbidden

Published version: archiving allowed

Upload

Policy details

Data provided by

Published in

Links

Tools

Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?